

# Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients

Verónica Pulito-Cueto<sup>1\*</sup>, Sara Remuzgo-Martínez<sup>1\*</sup>, Fernanda Genre<sup>1\*</sup>, Belén Atienza-Mateo<sup>1,2,3</sup>, Víctor M. Mora-Cuesta<sup>1,4</sup>, David Iturbe-Fernández<sup>1,4</sup>, Leticia Lera-Gómez<sup>1</sup>, Raquel Pérez-Fernández<sup>1</sup>, Diana Prieto-Peña<sup>1,3</sup>, Virginia Portilla<sup>1,3</sup>, Ricardo Blanco<sup>1,3</sup>, Alfonso Corrales<sup>1,3</sup>, Oreste Gualillo<sup>5</sup>, José M. Cifrián<sup>1,4,6</sup>, Raquel López-Mejías<sup>1\*\*</sup> and Miguel A. González-Gay<sup>1,3,6,7\*\*</sup>

**Table S1.** Differences of EPC frequency between SSc-ILD<sup>+</sup> patients and the three comparative groups (healthy controls, SSc-ILD<sup>-</sup> and IPF patients).

	EPC frequency (Mean $\pm$ SD)	<i>p</i>
SSc-ILD <sup>+</sup> patients vs healthy controls	0.033 $\pm$ 0.012 vs 0.013 $\pm$ 0.010	<b>&lt; 0.001</b>
SSc-ILD <sup>+</sup> patients vs SSc-ILD <sup>-</sup> patients	0.033 $\pm$ 0.012 vs 0.021 $\pm$ 0.017	<b>0.012</b>
SSc-ILD <sup>+</sup> patients vs IPF patients	0.033 $\pm$ 0.012 vs 0.087 $\pm$ 0.041	<b>&lt; 0.001</b>

EPC: endothelial progenitor cells; SSc: systemic sclerosis; ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; SD: standard deviation. Significant results are highlighted in **bold**.